Evidence map›Paper›PMID 28281872›Full record

ArticlemAbs

Novel anti-Sialyl-Tn monoclonal antibodies and antibody-drug conjugates demonstrate tumor specificity and anti-tumor activity.

Jillian M Prendergast, Ana Paula Galvao da Silva, David A Eavarone, Darius Ghaderi, Mai Zhang, Dane Brady, Joan Wicks, Julie DeSander, Jeff Behrens, Bo R Rueda

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in mAbs. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 51 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
51citing papers in PubMed, 1 pooled it
2.5field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

51 citing papers in PubMed, 1 synthesis or guideline pooled it, 85 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Review
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. The Role of Glycans in Human Immunity-A Sweet Code.Molecules (Basel, Switzerland) · 2025
    Review
  12. Review
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

Jillian M Prendergasta Siamab Therapeutics, Inc. , Newton , MA , USA.
Ana Paula Galvao da Silvaa Siamab Therapeutics, Inc. , Newton , MA , USA.
David A Eavaronea Siamab Therapeutics, Inc. , Newton , MA , USA.
Darius Ghaderia Siamab Therapeutics, Inc. , Newton , MA , USA.
Mai Zhanga Siamab Therapeutics, Inc. , Newton , MA , USA.
Dane Bradyb Alizée Pathology, LLC , Thurmont , MD , USA.
Joan Wicksb Alizée Pathology, LLC , Thurmont , MD , USA.
Julie DeSandera Siamab Therapeutics, Inc. , Newton , MA , USA.
Jeff Behrensa Siamab Therapeutics, Inc. , Newton , MA , USA.
Bo R Ruedac Vincent Center for Reproductive Biology, Department of Obstetrics and Gynecology , Massachusetts General Hospital , Boston , MA , USA.
Siamab Therapeutics (United States) · USMassachusetts General Hospital · US

Funding

Lead identification of therapeutic anti-glycan antibodies for cancer therapyR43CA186326 · NCI · SIAMAB THERAPEUTICS, INC. · PI PRENDERGAST, JILLIAN MARIE · 2015 to 2015
$220k
NCI NIH HHS HHSN261200700063CNCI NIH HHS HHSN261200900034CNCI NIH HHS R43 CA186326
6 · The paper itself

Abstract

Targeted therapeutics that can differentiate between normal and malignant tumor cells represent the ideal standard for the development of a successful anti-cancer strategy. The Sialyl-Thomsen-nouveau antigen (STn or Sialyl-Tn, also known as CD175s) is rarely seen in normal adult tissues, but it is abundantly expressed in many types of human epithelial cancers. We have identified novel antibodies that specifically target with high affinity the STn glycan independent of its carrier protein, affording the potential to recognize a wider array of cancer-specific sialylated proteins. A panel of murine monoclonal anti-STn therapeutic antibodies were generated and their binding specificity and efficacy were characterized in vitro and in in vivo murine cancer models. A subset of these antibodies were conjugated to monomethyl auristatin E (MMAE) to generate antibody-drug conjugates (ADCs). These ADCs demonstrated in vitro efficacy in STn-expressing cell lines and significant tumor growth inhibition in STn-expressing tumor xenograft cancer models with no evidence of overt toxicity.

Indexed as

Antibodies, Monoclonal, Murine-DerivedAntineoplastic Agents, ImmunologicalBreast NeoplasmsAnimalsAntigens, Tumor-Associated, CarbohydrateCell Line, TumorDrug Delivery SystemsFemaleHumansMiceMice, Inbred BALB COligopeptidesAntibodies, Monoclonal, Murine-DerivedAntigens, Tumor-Associated, CarbohydrateAntineoplastic Agents, ImmunologicalOligopeptidessialosyl-Tn antigensoblidotinAntibody Drug Conjugate (ADC)breast cancerCD175scolon cancerovarian cancersialyl-TnSTnTumor-Associated Carbohydrate Antigen (TACA)

Identifiers

PMID28281872
PMCPMC5419082
OpenAlexW2589361793

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.